{"id":"NCT01879319","sponsor":"Amgen","briefTitle":"Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen","officialTitle":"A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-11","primaryCompletion":"2013-11-15","completion":null,"firstPosted":"2013-06-17","resultsPosted":"2015-12-23","lastUpdate":"2022-11-30"},"enrollment":164,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab AMD","otherNames":["AMG 145","Repatha"]},{"type":"BIOLOGICAL","name":"Evolocumab AI/pen","otherNames":["AMG-145","Repatha"]}],"arms":[{"label":"Evolocumab AMD","type":"EXPERIMENTAL"},{"label":"Evolocumab AI/pen","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).","primaryOutcome":{"measure":"Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8","timeFrame":"Weeks 4 and 8","effectByArm":[{"arm":"Evolocumab AMD","deltaMin":93.9,"sd":null},{"arm":"Evolocumab AI/Pen","deltaMin":91.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":27,"countries":["United States","Canada"]},"refs":{"pmids":["28717862","29353350","28249876","32114889"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":82},"commonTop":[]}}